|
PE20220014A1
(es)
|
2019-04-29 |
2022-01-11 |
Univ Pennsylvania |
Nuevas capsides de aav y composiciones que las contienen
|
|
BR112021021908A2
(pt)
|
2019-05-03 |
2022-02-01 |
Univ Pennsylvania |
Composições úteis no tratamento da leucodistrofia metacromática
|
|
EP4085144A4
(en)
|
2019-12-19 |
2024-03-27 |
The Trustees of The University of Pennsylvania |
COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH AAXIA
|
|
MX2022012752A
(es)
|
2020-04-15 |
2023-01-16 |
Voyager Therapeutics Inc |
Compuestos de union a tau.
|
|
US20230304034A1
(en)
*
|
2020-05-12 |
2023-09-28 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
CN116096734A
(zh)
|
2020-05-13 |
2023-05-09 |
沃雅戈治疗公司 |
Aav衣壳的向性的重定向
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
US20230220069A1
(en)
|
2020-06-17 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
|
IL299762A
(en)
|
2020-07-13 |
2023-03-01 |
Univ Pennsylvania |
Useful preparations for the treatment of Charcot-Marietot disease
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
AU2021356684A1
(en)
*
|
2020-10-09 |
2023-05-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
IL302127A
(en)
|
2020-10-18 |
2023-06-01 |
Univ Pennsylvania |
An improved adeno-associated virus (AAV) vector and its uses
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
KR20230128001A
(ko)
*
|
2020-12-01 |
2023-09-01 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
엔젤만 증후군의 치료를 위한 조성물 및 이의 용도
|
|
EP4274592A4
(en)
*
|
2021-01-11 |
2025-03-19 |
The Trustees of The University of Pennsylvania |
COMPOSITIONS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
EP4308174A4
(en)
*
|
2021-03-19 |
2025-07-30 |
Mayo Found Medical Education & Res |
METHODS AND MATERIALS FOR THE TREATMENT OF PROPIONIC ACIDEMIA
|
|
US20230034817A1
(en)
|
2021-04-12 |
2023-02-02 |
Affinia Therapeutics Inc. |
Recombinant aav for treatment of neural disease
|
|
WO2023113806A1
(en)
|
2021-12-16 |
2023-06-22 |
Affinia Therapeutics, Inc. |
Recombinant aav for treatment of neural disease
|
|
AR125406A1
(es)
|
2021-04-23 |
2023-07-12 |
Univ Pennsylvania |
Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen
|
|
TW202309066A
(zh)
|
2021-04-27 |
2023-03-01 |
賓州大學委員會 |
衍生自豬的腺相關病毒衣殼及其用途
|
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4409010A1
(en)
|
2021-10-02 |
2024-08-07 |
The Trustees of The University of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
AU2022369293A1
(en)
*
|
2021-10-18 |
2024-05-16 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of cdkl5 deficiency disorder (cdd)
|
|
EP4430201A4
(en)
*
|
2021-11-12 |
2026-04-08 |
Univ Pennsylvania |
Gene therapy for the treatment of mucopolysaccharidosis IIIA
|
|
WO2023087019A2
(en)
*
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
TW202334181A
(zh)
|
2021-11-17 |
2023-09-01 |
美商航海家醫療公司 |
Ａａｖ蛋白殼變異體及其用途
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
EP4433490A2
(en)
|
2021-11-17 |
2024-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
AR128239A1
(es)
|
2022-01-10 |
2024-04-10 |
Univ Pennsylvania |
Composiciones y métodos útiles para el tratamiento de trastornos mediados por c9orf72
|
|
EP4469585A2
(en)
|
2022-01-25 |
2024-12-04 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
CA3249551A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
AAV Capsid Variants and Their Uses
|
|
US20250250326A1
(en)
|
2022-04-06 |
2025-08-07 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti-aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
|
JP2025512969A
(ja)
|
2022-04-06 |
2025-04-22 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｈｅｒ２陽性転移性乳がん及び他のがんを治療するための組成物及び方法
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023235791A1
(en)
|
2022-06-02 |
2023-12-07 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4543473A1
(en)
|
2022-06-22 |
2025-04-30 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
AR129733A1
(es)
|
2022-06-28 |
2024-09-25 |
Voyager Therapeutics Inc |
Variantes de cápsides de aav y sus usos
|
|
AR129843A1
(es)
|
2022-07-06 |
2024-10-02 |
Voyager Therapeutics Inc |
Variantes de la cápside de aav y usos de estas
|
|
EP4551253A1
(en)
*
|
2022-07-08 |
2025-05-14 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes
|
|
TW202435912A
(zh)
|
2022-08-03 |
2024-09-16 |
美商航海家醫療公司 |
用於穿過血腦屏障之組合物及方法
|
|
CA3266790A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
TAU PROTEIN BINDING COMPOUNDS
|
|
AU2023351041A1
(en)
*
|
2022-09-26 |
2025-03-13 |
Encoded Therapeutics, Inc. |
Elements for de-targeting gene expression in dorsal root ganglion and/or liver
|
|
KR20250135916A
(ko)
|
2022-12-17 |
2025-09-15 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
심장 및 골격근 특이적 표적화 모티프를 갖는 재조합 aav 돌연변이체 벡터 및 이를 포함하는 조성물
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
KR20250129743A
(ko)
|
2022-12-29 |
2025-08-29 |
보이저 테라퓨틱스, 인크. |
Mapt를 조절하기 위한 조성물 및 방법
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
WO2024226761A2
(en)
|
2023-04-26 |
2024-10-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating amyotrophic lateral sclerosis
|
|
EP4705324A1
(en)
|
2023-05-02 |
2026-03-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
|
CN121127597A
(zh)
|
2023-05-03 |
2025-12-12 |
沃雅戈治疗公司 |
用于治疗与葡糖苷酰鞘氨醇酶β1缺陷相关的病症的组合物及方法
|
|
WO2024229389A1
(en)
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
EP4705488A1
(en)
|
2023-05-04 |
2026-03-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2024235159A1
(zh)
*
|
2023-05-12 |
2024-11-21 |
上海金珂博生物技术有限公司 |
一种携带smn基因表达框的病毒载体及其用途
|
|
AR133098A1
(es)
|
2023-06-29 |
2025-08-27 |
Univ Pennsylvania |
Aav mutante con motivos dirigidos al sistema nervioso central y composiciones que lo contienen
|
|
IL326390A
(en)
|
2023-08-10 |
2026-04-01 |
Univ Pennsylvania |
Compositions and methods for treating spinal muscular atrophy
|
|
WO2025038805A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2025106661A1
(en)
|
2023-11-14 |
2025-05-22 |
The Trustees Of The University Of Pennsylvania |
Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
|
|
WO2025122644A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025122530A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025217023A1
(en)
*
|
2024-04-08 |
2025-10-16 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for gangliosidosis type 2 (gm2)
|
|
WO2025235734A2
(en)
|
2024-05-09 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2026010722A1
(en)
|
2024-07-03 |
2026-01-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for regulating mapt
|
|
WO2026028089A1
(en)
|
2024-07-29 |
2026-02-05 |
Novartis Ag |
Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
|